ECSP17038599A - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Info

Publication number
ECSP17038599A
ECSP17038599A ECIEPI201738599A ECPI201738599A ECSP17038599A EC SP17038599 A ECSP17038599 A EC SP17038599A EC IEPI201738599 A ECIEPI201738599 A EC IEPI201738599A EC PI201738599 A ECPI201738599 A EC PI201738599A EC SP17038599 A ECSP17038599 A EC SP17038599A
Authority
EC
Ecuador
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
sucralfate
ranitidine
Prior art date
Application number
ECIEPI201738599A
Other languages
Spanish (es)
Inventor
Sacher Eduard Sacher Gmbh Hotel
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17038599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of ECSP17038599A publication Critical patent/ECSP17038599A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para el tratamiento de enfermedades gastrointestinales que comprende ranitidina, sucralfato y subcitrato de bismuto como componentes activos y un método de preparación de los mismos. De acuerdo con la presente invención, cuando se prepara un fármaco de combinación de ranitidina, sucralfato y subcitrato de bismuto, es posible hacer frente a un problema de higroscopicidad de ranitidina y aumentar la estabilidad de la formulación y disponibilidad biológica de fármacos por medio del control de los tamaños de partícula de sucralfato y subcitrato de bismuto.A pharmaceutical composition for the treatment of gastrointestinal diseases comprising ranitidine, sucralfate and bismuth subcitrate as active components and a method of preparing them. According to the present invention, when a combination drug of ranitidine, sucralfate, and bismuth subcitrate is prepared, it is possible to cope with a problem of ranitidine hygroscopicity and increase the formulation stability and biological availability of drugs by controlling of sucralfate and bismuth subcitrate particle sizes.

ECIEPI201738599A 2015-01-30 2017-06-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES ECSP17038599A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
ECSP17038599A true ECSP17038599A (en) 2017-09-29

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201738599A ECSP17038599A (en) 2015-01-30 2017-06-20 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (2) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX375765B (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
WO2019199134A1 (en) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 Pharmaceutical composition comprising lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (en) * 1987-03-09 1993-03-04 Procter & Gamble COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
ATE213635T1 (en) * 1994-04-26 2002-03-15 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING MELT-GRANULATED SUCRALFATE PREPARATION
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
JP2001513570A (en) * 1997-08-25 2001-09-04 ザ、プロクター、エンド、ギャンブル、カンパニー Combination preparation for treatment of upper gastrointestinal upset
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
KR101617054B1 (en) * 2008-07-01 2016-04-29 라이온 가부시키가이샤 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
JP6419347B2 (en) 2018-11-07
WO2016122226A2 (en) 2016-08-04
EP3250199A4 (en) 2018-08-08
MX2017007567A (en) 2017-10-19
KR20160094268A (en) 2016-08-09
KR101583452B1 (en) 2016-01-11
PE20171340A1 (en) 2017-09-13
PH12017550051A1 (en) 2018-01-29
CN107205947B (en) 2020-05-22
GEAP201814551A (en) 2018-08-27
KR101583452B9 (en) 2022-05-02
TW201639559A (en) 2016-11-16
MA41432A (en) 2017-12-05
EA201791458A1 (en) 2017-11-30
GEP20186941B (en) 2019-01-10
WO2016122226A3 (en) 2016-09-15
SA517382016B1 (en) 2021-03-18
EA032385B1 (en) 2019-05-31
CL2017001680A1 (en) 2018-01-12
CN107205947A (en) 2017-09-26
JP2018503672A (en) 2018-02-08
BR112017013857A2 (en) 2018-02-27
AR105413A1 (en) 2017-10-04
CO2017006222A2 (en) 2017-09-20
TWI635859B (en) 2018-09-21
MX375765B (en) 2025-03-07
UA116517C2 (en) 2018-03-26
EA032385B9 (en) 2019-07-31
EP3250199A2 (en) 2017-12-06
GEP20196941B (en) 2019-01-10
MY195824A (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2018003388A (en) Farnesoid x receptor agonists and uses thereof.
NI201700011A (en) 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES.
MX394222B (en) NEW POLYMERIC PRODRUGS OF HUMAN GROWTH HORMONE (HGH).
NI201600144A (en) QUINOXALINE DERIVATIVES USEFUL AS MODULATORS OF FGFR KINASE
MX2019000588A (en) Somatostatin modulators and uses thereof.
UY37271A (en) NASAL CANNABINOID COMPOSITIONS
DOP2016000226A (en) ISOINDOLINONE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
MX376200B (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA.
MX389178B (en) FIXED RATIO FORMULATION OF INSULIN GLARGINE/LIXISENATIDE.
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
DK3168214T3 (en) SUBSTITUTED 2-THIOXO-IMIDAZOLIDIN-4-ONES AND SPIRO ANALOGUES THEREOF, ACTIVE ANTI-CANCER INGREDIENT, PHARMACEUTICAL COMPOSITION, MEDICINE PREPARATION, PROCEDURE FOR TREATMENT OF PROSTATANCES
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
CO2017007076A2 (en) Indenyl compounds, pharmaceutical compositions and medical uses thereof
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
DOP2016000161A (en) ASYMMETRIC UREAS P- SUBSTITUTED AND MEDICAL USES OF THE SAME.
CO2017006222A2 (en) Pharmaceutical composition for the treatment of gastrointestinal diseases
ZA201805408B (en) Medicament for treatment of diabetic foot infections
EA201891848A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS
ITUB20169928A1 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF DIABETES
GT201600190A (en) CHEMICAL COMPOUNDS
MX390488B (en) PHARMACEUTICAL COMPOSITION OF AMANTADINE HYDROCHLORIDE-LORATADINE-PARACETAMOL FOR INTEGRATING A CAPSULE, FOR THE TREATMENT OF COLDS AMONG OTHER ALLOPATHIES.
UY35989A (en) USE OF PARICALCITOL IN THE TREATMENT OF INFLAMMATORY ANEMIA
CL2018001236A1 (en) Pharmaceutical composition containing, as active ingredient, derivative of 7-azaindolin-2-one or pharmaceutically acceptable salt thereof.
BR112017003900A2 (en) testosterone formulations and treatment methods with them
BR112017018637A2 (en) 2,4 DIAMINO-QUINOLINE SUBSTITUTED AS NEW ANTICANCER AGENTS